Tyrosine kinase inhibitorPhase 3 trialInvestigational
Larotrectinib
How it works
Blocks the TRK protein, which fuels cancer cell growth.
Cancer types
Pancreatic Cancer— All patients
Prostate Cancer— NTRK-fusion positive
Efficacy
Studies show that larotrectinib can improve response rates in patients with NTRK-fusion positive metastatic castration-resistant prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Resistance to Cancer Drug in Some Patients with Lung Cancer | Lung Cancer | lab-study | Larotrectinib has a response rate of 75% across a wide range of solid tumors. | Source → |
| Larotrectinib Shows Promise in Treating Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 73% among 15 evaluable patients. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.